A similar strategy has already been validated in ALK-rearranged NSCLC, where the phase III ALINA trial established adjuvant alectinib as a standard of care, supporting a comparable evolution for ROS1-targeted therapy as randomized peri-operative data mature [69]. Here, ROS1 is linked to non-small cell lung carcinoma.